POTASSIUM-RICH FRUITS VERSUS POTASSIUM-POOR CITRUS PRODUCTS IN STONE RISK
POTASSIUM-RICH FRUITS VERSUS POTASSIUM-POOR CITRUS PRODUCTS IN STONE RISK
批准号:
7377614
负责人:
CLARITA V ODVINA
金额:
$2.48万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2007-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Administration of potassium citrate is now considered an effective treatment for recurrent urolithiasis. It has been shown to decrease stone formation rate in patients with idiopathic hypocitraturic calcium nephrolithiasis by as much as 72% in a placebo-controlled trial. Other studies have demonstrated that potassium citrate therapy can effectively reduce the rate of stone formation in hypocitraturic, hyperuricosuric, as well as in thiazide-unresponsive patients. The effect of potassium citrate is believed to be exerted through its citraturic and alkalinizing actions. Both potassium and citrate are nearly completely absorbed from the gastrointestinal tract. Citrate is nearly completely oxidized in vivo, but absorbed potassium is not metabolized. Thus, a "cation excess" is created, producing an alkali load. The alkali load enhances urinary citrate excretion by reducing renal tubular reabsorption of citrate. A small fraction of the absorbed citrate escapes oxidation in vivo and is excreted in the urine, contributing to the citraturic action of potassium citrate. The object of this study is to compare the urinary alkalinizing and citraturic effects of potassium-rich citrus fruit product (orange juice) with those of potassium-poor product (lemonade) under controlled metabolic conditions in both normal subjects and stone former.s
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RISK ASSESSMENT OF FRACTURES DURING BIPHOSPHATE TX BY ULTRASOUND WITH BQ1-H2
-
批准号:7606353
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2007
-
负责人:CLARITA V ODVINA
-
依托单位:
POTASSIUM-RICH FRUITS VERSUS POTASSIUM-POOR CITRUS PRODUCTS IN STONE RISK
-
批准号:7206014
-
项目类别:
-
资助金额:$8.53万
-
财政年份:2005
-
负责人:CLARITA V ODVINA
-
依托单位:
VENOUS BLOOD GAS IN PATIENTS ON COMBINED POTASSIUM CITRATE AND THIAZIDE THERAPY
-
批准号:7206041
-
项目类别:
-
资助金额:$0.04万
-
财政年份:2005
-
负责人:CLARITA V ODVINA
-
依托单位:
Effect of Weight Reducing Diet on Bone Loss and Stone Formation
-
批准号:6975053
-
项目类别:
-
资助金额:$9.15万
-
财政年份:2004
-
负责人:CLARITA V ODVINA
-
依托单位:
Potassium-rich fruits versus potassium-poor citrus products in stone risk
-
批准号:6975077
-
项目类别:
-
资助金额:$13.78万
-
财政年份:2004
-
负责人:CLARITA V ODVINA
-
依托单位:
Potassium-Magnesium Citrate in the Prevention of Hypomagnesemia
-
批准号:6975049
-
项目类别:
-
资助金额:$0.35万
-
财政年份:2004
-
负责人:CLARITA V ODVINA
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Rich2通过调控自噬抑制炎症小体NLRP3通路在癫痫形成中的机制研
究
-
批准号:
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2024
-
负责人:张小刚
-
依托单位:
前扣带回GTP酶激活蛋白RICH2介导Shank3-/-孤独症小鼠社交行为障碍的机制研究
-
批准号:82301350
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:张佳瑞
-
依托单位:
整合素β1/RICH1复合体感应细胞外基质硬度信号调控乳腺癌侵袭转移的机制研究
-
批准号:82303462
-
项目类别:青年科学基金项目
-
资助金额:30万元
-
批准年份:2023
-
负责人:田琦
-
依托单位:
转录因子NtMYB305通过AT-rich元件调控NtPMT表达及烟碱合成的分子机制研究
-
批准号:32101643
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:田田
-
依托单位:
Rich1/Amot-p80/Merlin轴通过Hippo通路调控乳腺癌干细胞样特性的机制研究
-
批准号:82002794
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:杨姣
-
依托单位:
烟草花叶病毒RNA发生poly(A)-rich型多聚腺苷酸化的研究
-
批准号:31370181
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2013
-
负责人:李为民
-
依托单位:
端粒延伸过程中C链合成(C-rich Fill-in)的分子机理
-
批准号:31271472
-
项目类别:面上项目
-
资助金额:90.0万元
-
批准年份:2012
-
负责人:赵勇
-
依托单位:
CA-rich顺式元件及其相互作用的反式因子对可变剪接的调控机制
-
批准号:30970620
-
项目类别:面上项目
-
资助金额:32.0万元
-
批准年份:2009
-
负责人:惠静毅
-
依托单位:
果蝇硒蛋白G-rich的细胞定位、拓扑结构和分子功能研究
-
批准号:30671176
-
项目类别:面上项目
-
资助金额:24.0万元
-
批准年份:2006
-
负责人:陈长兰
-
依托单位:
RICH/PHENIX相对论性重离子对撞实验中的μ子探测
-
批准号:10145008
-
项目类别:专项基金项目
-
资助金额:8.0万元
-
批准年份:2001
-
负责人:冒亚军
-
依托单位: